Active ingredient
- natalizumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.
This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.
For Healthcare Professionals
This form should be read carefully before continuing TYSABRI treatment for more than 2 years.
This form should be read carefully before discontinuing treatment with TYSABRI.
This form should be read carefully before starting treatment with TYSABRI.
If you would like to make a comment or send us feedback on this material, click here.
Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, UK
0800 008 7401
+44 (0)1628 501 010